Follow The Filings

ALLO Allogene Therapeutics Inc.

Health Care, filed as ALLOGENE THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 2 Owners
  • Max 0.8%
  • $4.2M
  • 1 add 1 small

In 2026 Q2 Nathan Fischel added to Allogene Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 0.8% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Add 0.79%

Who owns ALLO

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.79%, was 0.76% Add +46.0% 2,000,000 $4.2M History
Murray Stahl, Horizon Kinetics Asset Management <0.01% Small trim −4.6% 16,776 $35K History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ALLO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ALLO insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 15 sales to cover taxes and 2 option exercises.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
424B5 Filing Doc
8-K 5.07,8.01 Filing Doc
8-K 5.02 Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,1.02,2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $95,000 $22,000 $0.00
Net income -$327.26M -$257.59M -$190.89M
Net margin * -344489.5% -1170863.6% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $481.46M $303.39M $257.75M
Total non-current assets * $268.66M $245.32M $158.16M
Total assets $750.13M $548.71M $415.9M
Total current liabilities $59.4M $35.52M $32.51M
Total non-current liabilities * $98.72M $91.01M $90.85M
Total equity $592.01M $422.18M $292.54M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$237.73M -$200.3M -$149.25M
Cash from investing $163.29M $75.69M $95.56M
Cash from financing $95.7M $116.68M $30.16M
Net change in cash $21.25M -$7.94M -$23.53M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.